NCT Number: NCT06825715
The investigators are rolling out a 3 level intervention designed to improve the use of Precision Oncology at 8 VA medical centers. The 3 components of the intervention are 1: a short educational video for patients, 2: audit and feedback to providers on their Precision Oncology practice patterns, and 3: a change in the electronic medical record to make it easier to order and review results of Precision Oncology tests.
Interested in participating?
Request InfoAll sexes
Interventional
Not applicable
New York, 10010-5011, United States
Location status: Recruiting
Antoinette Vo, BA MA
CONTACT
212-686-7500 ext. 3922
Daniel J Becker, MD
CONTACT
(212) 686-7500 ext. 3303
Daniel J Becker, MD
PRINCIPAL_INVESTIGATOR
Background: Precision oncology (PO), the use of molecular testing to identify tumor specific abnormalities which facilitate targeted therapy, is proven to extend lives and improve quality of life for patients with cancer. Extensive study, however, documents that up to 50% of patients in the VA, especially those with adverse social determinants of health (older age, rural), do not receive guideline recommended PO.
Methodology: Building on the investigators' previous analyses, and the Theoretical Domains Framework, the investigators designed a mixed-methods type I hybrid effectiveness-implementation study of a multilevel intervention (MLI) to improve the use of PO. The MLI will be instituted for veterans with advanced cancers of the colon, lung, and prostate, as well as providers at 8 sites, chosen to represent diversity at the level of rurality, geographic region, cancer volume, and mode of delivery (virtual/in-person). The patient intervention is a 5-minute educational module accessible by QR code. The provider intervention is a 45-minute academic detailing session, as well as individualized audit and feedback on practice patterns. The facility level intervention is a previously piloted integration of PO ordering, interdepartmental communication, and results return into the primary electronic medical record via a consult function. The primary efficacy outcome is the rate of molecular testing/eligible veterans. Validated survey measures will be used for stakeholder engagement. The process evaluation employs a mixed methods approach based in the RE-AIM framework, which includes quantitative analyses of collected data, and interviews of patients and providers. The statistical design is a randomized stepped-wedge trial over 3 years which retains control data from across all sites.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
3 components: patient education video, provider audit/feedback, and EMR ordering change
Time frame: 3 years
Proportion of eligible patients with lung and prostate cancer who have next generation sequencing molecular testing
Time frame: 3 years
Proportion of patients with actionable molecular alterations who have targeted therapy.
Contact information is provided by the study sponsor or research team.
Antoinette Vo, BA MA
CONTACT
(212) 686-7500 ext. 3922
Daniel J Becker, MD
CONTACT
(212) 686-7500 ext. 3303
VA Office of Research and Development
Fed
Multilevel Veteran-centric Intervention to Improve Precision Oncology
Acronym: MIPO
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06471296
Cancer Anal Canal, Cancers of the Lung
Paris, France
View Trial Details